Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Collegium Pharmaceutical, Inc. - Common Stock (NQ:COLL)

32.06 -0.22 (-0.68%)
Streaming Delayed Price Updated: 9:37 AM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Collegium Pharmaceutical, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic... 
Via StockStory
News headline image
3 Cash-Producing Stocks Walking a Fine Line
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not... 
Via StockStory
News headline image
1 Value Stock on Our Buy List and 2 Facing Headwinds
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ... 
Via StockStory
Topics ETFs
News headline image
GE HealthCare and Collegium Pharmaceutical Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and pa... 
Via StockStory
Topics Economy Stocks World Trade
Collegium Pharmaceutical Inc (NASDAQ:COLL) Presents a Compelling Value Investment Case ↗
Via Chartmill
Collegium Pharmaceutical Inc (NASDAQ:COLL) Reports Q4 Revenue Growth but Misses Earnings Estimates ↗
Via Chartmill
COLLEGIUM PHARMACEUTICAL INC (NASDAQ:COLL) Presents a Classic Value Case with High Earnings and Low Valuation ↗
Via Chartmill
Collegium Pharmaceutical Inc (NASDAQ:COLL) Presents a Compelling Value Investment Case ↗
Via Chartmill
News headline image
2 Profitable Stocks to Consider Right Now and 1 We Question
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
Via StockStory
Topics Bonds
News headline image
Collegium's General Counsel Trims His Stake as the Company Doubles Down on ADHD ↗
This specialty pharma firm focused on pain management therapies reported a notable insider sale amid steady revenue and recent stock gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Branded Pharmaceuticals Stocks Q4 Recap: Benchmarking Collegium Pharmaceutical (NASDAQ:COLL)
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Collegium Pharmaceutical (NASDAQ:COLL) an... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Collegium Pharmaceutical EVP Sells Nearly 50,000 Shares Worth $2 Million ↗
Collegium Pharmaceutical, a leader in abuse-deterrent pain therapies, saw its Chief Commercial Officer trim his stake by more than 40%. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
BrightSpring Health Services, Collegium Pharmaceutical, and Phibro Animal Health Shares Are Soaring, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries. ... 
Via StockStory
Topics Economy Stocks
News headline image
3 Healthcare Stocks Walking a Fine Line
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have realiz... 
Via StockStory
News headline image
Why Collegium Pharmaceutical (COLL) Stock Is Trading Lower Today
Shares of pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) fell 6.7% in the afternoon session after the company reported fourth-quarter earnings and revenue that fell short of analysts'... 
Via StockStory
News headline image
Collegium (COLL) Q4 2025 Earnings Call Transcript ↗
Collegium (COLL) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Collegium Pharmaceutical’s (NASDAQ:COLL) Q4 CY2025 Earnings Results: Revenue In Line With Expectations
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 12.9% year on year to $205.4 million. The company’s full-year revenue... 
Via StockStory
News headline image
Collegium Pharmaceutical (COLL) Q4 Earnings: What To Expect
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting results this Thursday before market open. Here’s what to expect. 
Via StockStory
Topics World Trade
News headline image
1 Profitable Stock on Our Watchlist and 2 That Underwhelm
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
News headline image
Collegium Pharmaceutical EVP Sells COLL 17,600 Shares Amid Strong Close of 2025 ↗
An executive vice president at a top pharmaceutical company sold shares towards the end of 2025, while the company's shares reached record numbers that year. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Small-Cap Stocks We’re Skeptical Of
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
News headline image
3 Russell 2000 Stocks Walking a Fine Line
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the... 
Via StockStory
News headline image
2 Reasons to Avoid COLL and 1 Stock to Buy Instead
Collegium Pharmaceutical has been on fire lately. In the past six months alone, the company’s stock price has rocketed 68.7%, setting a new 52-week high of $49.89 per share. This was partly thanks to... 
Via StockStory
Topics Supply Chain
News headline image
3 Cash-Producing Stocks We Think Twice About
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
Collegium Pharmaceutical Inc (NASDAQ:COLL) Shows Strong Earnings Momentum and Bullish Technical Setup ↗
Collegium Pharmaceutical (COLL) shows strong earnings growth and a bullish technical setup, offering a potential breakout opportunity for momentum investors. 
Via Chartmill
News headline image
3 Unpopular Stocks We Find Risky
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other... 
Via StockStory
News headline image
Collegium Pharmaceutical Inc (NASDAQ:COLL) Fits the Minervini Growth Momentum Strategy ↗
Collegium Pharmaceutical (COLL) aligns with Mark Minervini's SEPA strategy, showing a strong technical uptrend and robust fundamental earnings and sales growth. 
Via Chartmill
News headline image
Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Collegium Pharmaceutical (NASDAQ:COLL)
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Collegium Pharmaceutical (NASDAQ:COLL) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
1 Growth Stock Set to Flourishand 2 Facing Challenges
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who... 
Via StockStory
News headline image
1 Mooning Stock with Promising Prospects and 2 Facing Challenges
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions. 
Via StockStory
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.